Möchten Sie immer auf dem neuesten Stand bleiben?

  Not intended for UK audiences  Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2Affecting up to 100,000...

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years.PPF is a rare lung condition, more life-threatening than many...

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been...

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's...

First-ever use of Ebenbuild’s Twinhale technology  in idiopathic pulmonary fibrosis lung modelsTrial results published in Nature Communications Munich, Germany – April 9, 2025 -- Ebenbuild, a company...

New York, United States, March 06, 2025 (GLOBE NEWSWIRE) -- Idiopathic pulmonary fibrosis is a progressive, chronic lung disease that affects people aged 50 to 70. Breathlessness and a dry,...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Global Cystic Fibrosis Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global cystic...

Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Pulmonary Fibrosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...

Surrozen Provides First Quarter 2024 Financial Results and Business Update